World's Best Scientists 2026 revealed!
Alexandros Makriyannis

Alexandros Makriyannis

D-Index & Metrics

Medicine

D-Index
100
Citations
36218
World Ranking
8287
National Ranking
4288

Chemistry

D-Index
96
Citations
34149
World Ranking
1540
National Ranking
591

Alexandros Makriyannis publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Alexandros Makriyannis sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 563 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Alexandros Makriyannis D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Alexandros Makriyannis sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 96 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Research.com Recognitions

  • 1993 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Alexandros Makriyannis is affiliated with Northeastern University in the United States. Their primary fields of study include Medicine and Neuroscience, with a prominent focus on Pharmacology, Cellular and Molecular Neuroscience, Molecular Biology, Physiology, and Cognitive Neuroscience.

The research topics covered by Alexandros Makriyannis primarily center around Cannabis and Cannabinoid Research, Neuroscience and Neuropharmacology Research, Pharmacological Receptor Mechanisms and Effects, Sleep and Wakefulness Research, Neurotransmitter Receptor Influence on Behavior, Diet, Metabolism, and Disease, as well as Pain Mechanisms and Treatments.

Makriyannis has contributed to frequent publications in several venues, notably:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Medicinal Chemistry
  • Journal of Pharmacology and Experimental Therapeutics
  • Nature
  • Nature Communications

Among recent publications by Alexandros Makriyannis, key papers include:

  • "Synthon-based ligand discovery in virtual libraries of over 11 billion compounds" (2021, Nature)
  • "Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures" (2020, Cell)
  • "Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years" (2023, Pharmacological Reviews)
  • "A Genetically Encoded F-19 NMR Probe Reveals the Allosteric Modulation Mechanism of Cannabinoid Receptor 1" (2021, Journal of the American Chemical Society)
  • "Structural basis for activation of CB1 by an endocannabinoid analog" (2023, Nature Communications)

The scientist frequently collaborates with other researchers, including:

  • Spyros P. Nikas
  • Christos Iliopoulos-Tsoutsouvas
  • Michael S. Malamas
  • Lipin Ji
  • Kiran Vemuri

Alexandros Makriyannis was awarded the title of Fellow of the American Association for the Advancement of Science (AAAS) in 1993.

Best Publications

  • Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors

    Marja D. Van Sickle;Marnie Duncan;Philip J. Kingsley;Abdeslam Mouihate

  • Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition

    M. Beltramo;N. Stella;N. Stella;N. Stella;A. Calignano;A. Calignano;A. Calignano;S. Y. Lin;S. Y. Lin;S. Y. Lin

  • A new antibiotic selectively kills Gram-negative pathogens

    Yu Imai;Kirsten J. Meyer;Akira Iinishi;Quentin Favre-Godal

  • CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.

    Mohab M. Ibrahim;Frank Porreca;Josephine Lai;Phillip J. Albrecht

  • Crystal Structure of the Human Cannabinoid Receptor CB2.

    Tian Hua;Kiran Vemuri;Mengchen Pu;Lu Qu;Lu Qu

  • Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS

    Mohab M. Ibrahim;Hongfeng Deng;Alexander Zvonok;Debra A. Cockayne

  • Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.

    Ruoxi Lan;Qian Liu;Pusheng Fan;Sonyuan Lin

  • Synthon-based ligand discovery in virtual libraries of over 11 billion compounds

    Unknown

  • Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

    Joseph Tam;V. Kiran Vemuri;Jie Liu;Sándor Bátkai

  • Crystal structures of agonist-bound human cannabinoid receptor CB1

    Tian Hua;Kiran Vemuri;Spyros P. Nikas;Robert B. Laprairie

  • CB2 cannabinoid receptor-mediated peripheral antinociception.

    T.Philip Malan;Mohab M. Ibrahim;Hongfeng Deng;Qian Liu

  • Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

    Ruth A Ross;Heather C Brockie;Lesley A Stevenson;Vicki L Murphy

  • Endocannabinoids control spasticity in a multiple sclerosis model

    D Baker;G Pryce;J L Croxford;P Brown

  • Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

    Sándor Bátkai;Zoltán Járai;Jens A. Wagner;Sravan K. Goparaju

  • Functional CB1 cannabinoid receptors in human vascular endothelial cells.

    Jie Liu;Bin Gao;Faridoddin Mirshahi;Arun J. Sanyal

  • (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.

    Vasiliki Abadji;Sonyuan Lin;Gihan Taha;Graeme Griffin

  • Structural determinants for recognition and translocation by the anandamide transporter.

    D. Piomelli;M. Beltramo;S. Glasnapp;S. Y. Lin

  • Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

    O. Gunduz-Cinar;K. P. MacPherson;R. Cinar;J. Gamble-George

  • Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-GiComplex Structures.

    Tian Hua;Xiaoting Li;Lijie Wu;Christos Iliopoulos-Tsoutsouvas

  • 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.

    S.John Gatley;Andrew N. Gifford;Nora D. Volkow;Ruoxi Lan

  • Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.

    Aline Quartilho;Heriberto P. Mata;Mohab M. Ibrahim;Todd W. Vanderah

  • Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172

    D. Fegley;S. Kathuria;R. Mercier;C. Li

Frequent Co-Authors

Ben A. Bahr
Ben A. Bahr University of North Carolina at Pembroke
John D. Salamone
John D. Salamone University of Connecticut
Marcus A. Tius
Marcus A. Tius University of Hawaii at Manoa
Roger G. Pertwee
Roger G. Pertwee University of Aberdeen
Todd W. Vanderah
Todd W. Vanderah University of Arizona
Stephen W. Fesik
Stephen W. Fesik Vanderbilt University
Frank Porreca
Frank Porreca University of Arizona
Daniele Piomelli
Daniele Piomelli University of California, Irvine
Nora D. Volkow
Nora D. Volkow National Institutes of Health
Ken Mackie
Ken Mackie Indiana University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying chemistry in the USA opens doors to a variety of career options, many of which can be enhanced through specialized degrees and certifications. For those interested in support roles within the legal and scientific fields, pursuing a paralegal associate degree can provide a strong foundation, particularly in cases involving chemical patents or regulatory compliance.

The pharmaceutical industry offers dynamic career paths for chemistry graduates. Many find rewarding opportunities as pharmaceutical sales representatives, a role that combines science knowledge with business skills. Understanding how much do drug reps make can help set realistic expectations and guide career planning in this sector.

For those passionate about healthcare, becoming a pharmacist is a prestigious yet demanding option. It's important to know is it hard to become a pharmacist, as this path requires rigorous education and certification but offers excellent job security and impact on patient health.

Another niche but vital career is working as an autopsy technician. Chemistry graduates might consider specialized training programs to enter this field, and learning about autopsy tech education, salary, and job outlook can provide clarity on the opportunities and challenges ahead.

Best Scientists Citing Alexandros Makriyannis

Trending Scientists

Recently Published Articles